![]() |
Market Research Report
Product code
1047136
Insulin Glargine- - Biosimilar Insight, 2022 |
Insulin Glargine- - Biosimilar Insight, 2022 |
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 90 Pages
Delivery time: 2-10 business days
|
DelveInsight's, "Insulin Glargine- Biosimilar 2022," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Insulin Glargine Understanding
Insulin Glargine: Overview
Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes. It is typically the recommended long acting insulin in the United Kingdom. It is used once a day as an injection just under the skin. Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from endogenous human insulin by the replacement of an asparagine residue at position A21 of the A-chain with glycine and addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action and no pronounced peak concentration.
Insulin Glargine Biosimilars: Drugs Chapters
This segment of the Insulin Glargine report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Insulin Glargine Biosimilars: Marketed Drugs
Semglee contains insulin glargine. This is a modified insulin, very similar to human insulin. Semglee is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar.
Insulin glargine biosimilar (Abasaglar) is licensed for the treatment of diabetes mellitus in adults, young people and children over 2 years. Abasaglar is a basal insulin for once daily use and is bioequivalent to insulin glargine (Lantus). Basaglar is not approved for use by anyone younger than 6 years old, and should not be used to treat type 2 diabetes in a child of any age.
Further product details are provided in the report……..
Insulin Glargine Biosimilars: Emerging Drugs
Insulin RinGlar is being developed by Geropharm for the treatment of Type 1 diabetes mellitus. This is the fifth insulin in the company portfolio, which will complete the Geropharm line of human recombinant insulins and analogues. RinGlar will become the first insulin glargine, which will be produced in Russia on a full cycle basis - from substance to the finished dosage form.
Further product details are provided in the report……..
Insulin Glargine: Therapeutic Assessment
This segment of the report provides insights about the different Insulin Glargine biosimilars segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Insulin Glargine.
DelveInsight's report covers around 10+ products under different phases of clinical development like
Insulin Glargine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Insulin Glargine: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Insulin Glargine biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Insulin Glargine biosimilar drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products